Cover of Diabetes Connections | Type 1 Diabetes

Diabetes Connections | Type 1 Diabetes

Diabetes Connections | Type 1 Diabetes

By: Stacey Simms
Listen for free

Season's Savings | 0.99 €/month for 3 months

5.99 €/month thereafter - terms apply. Cancel monthly.
Summary
 Hosted by award-winning broadcaster and journalist Stacey Simms, Diabetes Connections brings a reporter's perspective to the world of diabetes. Since 2015, Stacey has gone beyond the headlines to ask tough questions, break down the latest research and technology, and share honest conversations with the people shaping diabetes care. From industry leaders and researchers to everyday people living with diabetes, Diabetes Connections delivers the news you need, the stories you love, and the questions you want answered. Smart, engaging, and always focused on the diabetes community.Stacey Simms Media 2015-2026 Hygiene & Healthy Living Physical Illness & Disease
Episodes
  • Can a 100-Old Vaccine Impact Type 1 Diabetes? A Conversation with Dr. Denise Faustman

    Can a 100-Old Vaccine Impact Type 1 Diabetes? A Conversation with Dr. Denise Faustman
    10 Nov 2026

    This week on Diabetes Connections - looking into a very old vaccine to get new results for people with type 1. Dr. Denise Faustman's research into the BCG vaccine has been making headlines for a long time, and she's now sharing new results from her clinical trials, including some pretty remarkable claims about A1C, insulin use, and time in range.

    Now, I know some of you may be surprised that I'm having Dr. Faustman on the show. She's a very controversial figure in the diabetes research world, and her work has sparked plenty of debate and skepticism over the years.

    We're not ignoring any of that. In fact, we talk directly about the controversy, why she believes her research has faced resistance, and what it would take for BCG to become a widely accepted treatment.

    This podcast is not intended as medical advice if you have those kinds of questions please contact your healthcare provider.

    More about Dr. Faustman's work here

    More about the controversy and history here

    Check out all of our events like Moms' Night Out and Club 1921 here.

    Announcing Community Commericals! Learn how to get your message on the show here.
    Learn more about studies and research at Thrivable here
    Please visit our Sponsors & Partners - they help make the show possible!
    Omnipod - Simplify Life
    All about Dexcom
    All about VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
    Sign up for our newsletter here

    Here's where to find us:
    Facebook (Group)
    Facebook (Page)
    Instagram
    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Show more Show less
    39 min
  • In the News... CGM Coverage, Why A1C vs GMI Matters, Fully Implantable CGM Trialed, T1D at the NYC Marathon and more

    In the News... CGM Coverage, Why A1C vs GMI Matters, Fully Implantable CGM Trialed, T1D at the NYC Marathon and more
    3 Nov 2026
    This week on Diabetes Connections In the News… big insurance changes could affect your CGM coverage, a new study looks at why the difference between estimated A1C from CGM and the A1C from the lab could really matter to your health, Eversense CGM starts testing a new version that's completely below the skin, news about heart health and type 1, the next generation of weight loss drug and a big week for sports on the highest level with type 1. And it's diabetes awareness momth! It's all coming up right after this. (AD BREAK) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Diabetes Awareness Month – I've got some news there, but there are SO many campaigns and releases this month. I've always said it's always diabetes awareness month around here and these awareness campaigns are for the engeral ppulario. So I'm sure you're inundated – I'll highlight what I think it noteworthy. We're in Phoenix this week for our last in person event of the year. This is a Club 1921 event for the whole community. We will have more of these next year – but our Next in person event will be Tampa in March for MNO – that's open and we have a flash sale until the end of this month. Okay.. our top story this week: XX Some people with diabetes may have to switch continuous glucose monitors starting January 1, 2027, because of insurance coverage changes involving CVS Caremark and Aetna. According to the Diabetes Patient Advocacy Coalition, some plans are moving to exclusive contracts that favor Abbott's FreeStyle Libre over Dexcom. Not everyone will be affected, and some patients may still be able to get their preferred CGM covered through medical rather than pharmacy benefits. DPAC is pushing back, arguing that insurance contracts shouldn't force people to change diabetes technology that's working for them. The organization is encouraging people to contact CVS Caremark and Aetna leadership through its online advocacy campaign. https://diabetespatientadvocacycoalition.quorum.us/campaign/cgmcvs XX Dexcom is facing criticism from the diabetes community after users were presented with updated terms and conditions as they used the app. Statement from Dexcom: We understand the concerns surrounding our roll out of our Terms of Use and Privacy Notice and recognize the importance of providing users with clear information. These updates are intended to support the continued operation, security and innovation of our products, while providing greater transparency into how data may be collected and used. We take our responsibility to protect users' personal information seriously and remain committed to handling their data responsibly. Like many digital services, continued use of the Dexcom app requires acceptance of the updated Terms of Use. Moving forward, users will have 30 days from acceptance to opt out of the arbitration provisions and may also opt out of certain cookies and data-sharing activities at any time. We understand the importance of uninterrupted access to glucose data for people managing diabetes. We are reviewing how we communicate and implement changes like these in the future to ensure users have the information they need and a clear understanding of their choices. XX Senseonics announced the initiation of its first-in-human clinical study evaluating Freedom, an investigational next-generation CGM system designed to communicate directly with a mobile device without the need for an external on-body transmitter. Unlike the current Eversense, which uses a removable transmitter worn over the implanted sensor, Freedom is designed to communicate directly with a smartphone using Bluetooth. The initial study will focus on safety, design, and wireless communication. Senseonics hopes to begin a larger clinical trial in 2027, with a possible commercial launch in 2028 if development and regulatory review go as planned. Source: Drug Delivery Business News XX In patients with type 1 diabetes (T1D), having a laboratory A1c higher than the glucose management indicator (GMI), your CGM, was associated with more microvascular complications. Researchers in Spain studied more than 1,300 adults with type 1 diabetes and found that people whose laboratory A1C was significantly higher than their CGM estimate were more likely to have complications involving their eyes, kidneys, or nerves. Those with the largest discrepancies had nearly twice the odds of these complications, even after researchers accounted for other clinical and CGM measurements. The study doesn't establish that the mismatch causes complications, but researchers say looking at both numbers together may help doctors better assess individual risk. Source: Medscape XX New research ...
    Show more Show less
    13 min
  • What We Learned at the Very First Breakthrough T1D Clinical & Research Congress, with Anastasia Albanese-O'Neill

    What We Learned at the Very First Breakthrough T1D Clinical & Research Congress, with Anastasia Albanese-O'Neill
    27 Oct 2026

    What happened at the very first Breakthrough T1D Clinical and Research Congress? More than a thousand people from 33 countries came together to talk about everything from islet cell transplants and new treatments to screening, prevention, and the growing role of GLP-1 medications in type 1 diabetes.

    I'm talking to Anastasia Albanese-O'Neill, vice president, medical affairs for Breakthrough, who joins us fresh off the conference to share the biggest headlines, what she's most excited about, and why she says we're at an inflection point in type 1 diabetes care.

    We also talk about how even the most promising breakthrough won't make a difference unless people can actually access it.

    This podcast is not intended as medical advice if you have those kinds of questions please contact your healthcare provider.

    More about the Congress here

    Check out all of our events like Moms' Night Out and Club 1921 here.

    Announcing Community Commericals! Learn how to get your message on the show here.
    Learn more about studies and research at Thrivable here
    Please visit our Sponsors & Partners - they help make the show possible!
    Omnipod - Simplify Life
    All about Dexcom
    All about VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
    Sign up for our newsletter here

    Here's where to find us:
    Facebook (Group)
    Facebook (Page)
    Instagram
    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Show more Show less
    32 min
adbl_web_anon_alc_button_suppression_t1
No reviews yet